DADC
ADMA icon

D.A. Davidson & Co’s ADMA Biologics ADMA Stock Holding History

D.A. Davidson & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,480
Closed -$227K – 1524
2025
Q3 		$227K Sell
15,480
-14,580
-49% -$250K ﹤0.01% 1413
2025
Q2 		$547K Buy
30,060
+5,300
+21% +$108K ﹤0.01% 1012
2025
Q1 		$491K Buy
24,760
+13,000
+111% +$225K ﹤0.01% 1026
2024
Q4 		$202K Buy
+11,760
New +$221K ﹤0.01% 1338

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

D.A. Davidson & Co's ADMA Position: Q4 2025 in Review

D.A. Davidson & Co sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 15,480 shares — an estimated $227K sold.

D.A. Davidson & Co first reported a position in ADMA in Q4 2024 and held it in 4 quarters. The position peaked at $547K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • D.A. Davidson & Co reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 15,480 ADMA Biologics shares in Q4 2025, an estimated $227K.
  • D.A. Davidson & Co first reported a position in ADMA Biologics in Q4 2024 and held it in 4 quarters.
  • D.A. Davidson & Co's ADMA Biologics position peaked at $547K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on D.A. Davidson & Co's 13F filing for Q4 2025, filed 29 Jan 2026.